La vendita allo scoperto per Theriva Biologics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Theriva Biologics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Theriva Biologics (AMEX:TOVX) Azioni, Report sulle vendite allo scoperto

Theriva Biologics

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Theriva Biologics Inc

Goldman Sachs analyst Kash Rangan maintains Weave Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEAV#NYSE">WEAV</a>) with a Neutral and raises the price target from $13 to $14.5.

News

Price Target

Analyst Ratings

WEAV

Goldman Sachs Maintains Neutral on Weave Communications, Raises Price Target to $14.5

RBC Capital analyst Brad Heffern maintains NNN REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>) with a Sector Perform and lowers the price target from $48 to $45.

RBC Capital Maintains Sector Perform on NNN REIT, Lowers Price Target to $45

Goldman Sachs analyst Chris Shibutani maintains United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Neutral and raises the price target from $243 to $302.

UTHR

Goldman Sachs Maintains Neutral on United Therapeutics, Raises Price Target to $302

RBC Capital analyst Arun Viswanathan maintains O-I Glass (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OI#NYSE">OI</a>) with a Outperform and lowers the price target from $18 to $16.

RBC Capital Maintains Outperform on O-I Glass, Lowers Price Target to $16

Goldman Sachs analyst Brian Lee maintains Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) with a Neutral and lowers the price target from $0.75 to $0.65.

STEM

Goldman Sachs Maintains Neutral on Stem, Lowers Price Target to $0.65

Jim Cramer, the well-known stock market commentator, set social media buzzing this week after he tweeted about Reddit&#8217;s stellar earnings report, putting it on par with Google&#8217;s results.&nbsp;
Cramer <a href="https://x.com/jimcramer/status/1851547876419051779">acknowledged</a> that it&#8217;s difficult to determine which of the two tech behemoths made more money, referring to Reddit&#8217;s revenues as &#8220;amazing.&#8221; Considering Google&#8217;s dominance in the tech industry, this is quite the endorsement.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">It&#39;s tough to tell which one is better -Reddit or Google. I am not kidding, Reddit was amazing
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1851547876419051779?ref_src=twsrc%5Etfw">October 30, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's an opportunity to invest at $1,000 for only $0.50/share today.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a></li>
</ul>
Cramer's tweet may seem surprising, especially as Google has long been one of the world's tech giants. However, it shows how Reddit has evolved into a successful company that can contend for investors&#8217; and users&#8217; attention.
Both businesses produced impressive third-quarter earnings that surpassed forecasts, which prompted the comparison. Despite an anticipated loss of 8 cents per share, Reddit&#8217;s performance has been good, <a href="https://www.benzinga.com/news/earnings/24/10/41633983/reddit-stock-is-ripping-higher-wednesday-whats-happening">with earnings of 16 cents per share</a>.&nbsp;
Revenue also surpassed estimates, coming in at $348.4 million, and the company&#8217;s gross margin improved to 90.1%. Perhaps the most noteworthy figure was the 47% rise in daily active users to 97.2 million. For the first time since its March IPO, Reddit turned a profit.
See Also: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a>
Wall Street was also captivated by Reddit&#8217;s optimistic outlook. The company expects fourth-quarter revenue between $385 million and $400 million, outpacing the analyst estimate of $356.7 million.&nbsp;
As a result of Reddit&#8217;s impressive performance, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41631795/reddit-remains-a-favorite-for-wall-street-after-emphatic-beat-and-raise-in-q3">analysts promptly modified their projections</a>. Roth MKM increased from $89 to $116, Piper Sandler from $70 to $115, and&nbsp;
Needham increased its price objective from $85 to $120.
However, Google also had a fantastic quarter. The tech behemoth <a href="https://www.benzinga.com/markets/equities/24/10/41629264/alphabets-earnings-rally-pushes-magnificent-7-market-cap-to-record-16-8-trillion-10-tech-heavy-e">beat analyst projections</a> of $1.83 per share with earnings of $2.12 per share. Cloud revenue increased 35% year over year to $11.4 billion, contributing to the $88.27 billion in revenue. Advertising revenue also rose, beating estimates at $65.85 billion.&nbsp;
Trending: If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?
The appeal of new AI features like AI Overviews, which currently serve 1 billion users each month, and the robust growth of Google&#8217;s cloud business was highlighted by CEO Sundar Pichai. With CFO Anat Ashkenazi declaring a $13 billion budget for the upcoming quarter, Google intends to continue making significant investments in AI and data technology.
Despite the positive numbers from both companies, what really stands out is the sentiment surrounding Reddit. Jim Cramer&#8217;s excited tweet suggests a change in public opinion. Reddit is becoming more popular as a strong platform with genuine commercial value in addition to being a social community. The company&#8217;s notable revenue growth, increased user base, and enhanced profitability are creating a stir.
Read Next:
<ul>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
<li>With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai">Be an early investor with just $1,000 for only $0.50/share today.</a></li>
</ul>

Startups

'I'm Not Kidding, Reddit Was Amazing' — Jim Cramer Compares Reddit To Google, Saying Choosing Between Them Isn't Easy

Goldman Sachs analyst Kate McShane maintains Sprouts Farmers Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) with a Buy and raises the price target from $127 to $159.

Goldman Sachs Maintains Buy on Sprouts Farmers Market, Raises Price Target to $159

RBC Capital analyst Deane Dray reiterates Eaton Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) with a Outperform and maintains $374 price target.

Reiteration

RBC Capital Reiterates Outperform on Eaton Corp, Maintains $374 Price Target

Solana's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) ecosystem showed notable financial and institutional growth in the year&#8217;s third quarter, securing $173 million in new funding across 29 projects despite a slowdown in the number of funding rounds, according to a new Messari report.
What Happened: This 54% quarter-over-quarter increase represents the highest quarterly funding total since Q2 2022, highlighting investor confidence in Solana&#8217;s infrastructure and DeFi solutions, Messari writes.
A notable aspect of Solana's growth is its appeal to institutional giants. 
&#8220;Solana has caught the attention of major players like Visa, PayPal, and Franklin Templeton, each of whom expanded operations on Solana this quarter," the report states. 
With Solana now holding $123 million in tokenized treasuries, it ranks third globally in this category, trailing only Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) and Stellar, and edging closer to rivaling Ethereum's dominance. 
This stronghold in tokenized treasuries reflects a "shifting landscape" in blockchain adoption, with more financial entities recognizing the unique offerings of Solana's network.
Messari&#8217;s report further highlights key advancements in Solana's infrastructure. 
The Q3 launch of Solana's V1.18 upgrade and the live deployment of Firedancer on the mainnet in non-voting mode significantly enhanced transaction scheduling and block production capabilities. 
The addition of Light Protocol and Helius's ZK Compression solution also aimed to address scaling, an area where Solana continues to make strides.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41690129/borderless-integrates-with-fireblocks-to-enhance-fiat-to-crypto-payment-capabilities">Borderless Integrates With Fireblocks To Enhance Fiat-to-Crypto Payment Capabilities</a>
&#8220;The real-time upgrades and attention to network efficiency are vital as Solana prepares to scale further,&#8221; says the report, suggesting that Solana's technical advances are setting it apart in the competitive landscape of blockchain networks.
Solana's DeFi sector has also seen robust growth, with a 26% rise in total value locked (TVL), reaching $5.7 billion. 
This development placed Solana ahead of Tron (CRYPTO: TRON) by the end of September and signals heightened DeFi activity on the network. 
Kamino, a DeFi protocol within Solana, saw notable growth, with its TVL hitting $1.5 billion, propelled by PayPal's USD stablecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PYUSD</a>) and other assets. 
"These TVL increases highlight a surging interest in DeFi products on Solana, particularly those focused on yielding higher returns," the report observes, adding that innovations such as Kamino's lending orderbook and spot leverage are set to bolster Solana's DeFi market presence.
In terms of adoption, stablecoin PYUSD marked a new milestone, ending Q3 with a 341% increase in circulating market cap on Solana. 
"Institutional interest isn't just a phase," the report emphasizes, "it reflects a broader shift where major financial entities view Solana as a reliable network for their blockchain ambitions."
As Solana moves into Q4, it continues to attract attention from both institutional and retail users, evident from its $71 billion market cap—an increase of 5% from the previous quarter. 
What&#8217;s Next: For a comprehensive look at how these developments impact the broader market, Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19 offers timely insights.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41687739/nate-silver-says-kamala-harris-may-need-backup-plans-if-the-blue-wal-is-split-but-sees-the">Nate Silver Says Kamala Harris &#8216;May Need Backup Plans&#8217; If The &#8216;Blue Wall&#8217; Is Split But Sees The Race As &#8216;A Near Coin Flip&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

$PYUSD

$SOL

Solana Sees $173M Funding Surge In Q3 Amid Rising Institutional Interest From PayPal, Visa, Franklin Templeton

Goldman Sachs analyst Caitlin Burrows maintains Safehold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAFE#NYSE">SAFE</a>) with a Buy and lowers the price target from $38 to $30.

SAFE

Goldman Sachs Maintains Buy on Safehold, Lowers Price Target to $30

Goldman Sachs analyst Eric Sheridan maintains Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Neutral and raises the price target from $45 to $55.

RBLX

Goldman Sachs Maintains Neutral on Roblox, Raises Price Target to $55

Barclays analyst Manav Patnaik maintains WillScot Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSC#NASDAQ">WSC</a>) with a Equal-Weight and lowers the price target from $44 to $40.

Barclays Maintains Equal-Weight on WillScot Holdings, Lowers Price Target to $40

Goldman Sachs analyst Will Nance maintains Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) with a Neutral and lowers the price target from $25 to $22.

HOOD

Goldman Sachs Maintains Neutral on Robinhood Markets, Lowers Price Target to $22

Goldman Sachs analyst Lizzie Dove maintains Norwegian Cruise Line (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) with a Neutral and raises the price target from $24 to $29.

NCLH

Goldman Sachs Maintains Neutral on Norwegian Cruise Line, Raises Price Target to $29

RBC Capital analyst Brad Heffern maintains Equity Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQR#NYSE">EQR</a>) with a Outperform and lowers the price target from $83 to $79.

RBC Capital Maintains Outperform on Equity Residential, Lowers Price Target to $79

Goldman Sachs analyst Eric Sheridan maintains MediaAlpha (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAX#NYSE">MAX</a>) with a Buy and raises the price target from $20 to $26.

Goldman Sachs Maintains Buy on MediaAlpha, Raises Price Target to $26

Goldman Sachs analyst Alexander Blostein maintains LPL Finl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>) with a Buy and raises the price target from $271 to $305.

LPLA

Goldman Sachs Maintains Buy on LPL Finl Hldgs, Raises Price Target to $305

Meta Platforms Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) third-quarter earnings show a $4.4 billion loss for its augmented and virtual reality division, Reality Labs, marking the third consecutive quarterly loss for the <a href="https://www.benzinga.com/news/earnings/24/10/41637326/meta-platforms-q3-earnings-revenue-beat-eps-beat-daily-actives-up-5-strong-momentum-in-ai">segment this year. </a>
Previous quarters in 2024 had losses of $3.8 billion and $4.5 billion, GamesIndustry.biz <a href="https://www.gamesindustry.biz/metas-arvr-reality-labs-division-records-further-losses-of-44-billion">reported.</a>
<h1 class="wp-block-heading">Revenue Increase Tied To Hardware Sales</h1>
Despite ongoing losses, Reality Labs reported a 29% revenue increase in the third quarter, totaling $270 million, driven by strong hardware sales.
See Also: <a href="https://www.benzinga.com/news/24/10/41674206/jim-cramer-says-mark-zuckerberg-has-your-brain-as-meta-pours-billions-into-global-domination-strateg">Jim Cramer Says Mark Zuckerberg Has &#8216;Your Brain&#8217; As Meta Pours Billions Into Global Domination Strategy</a>
However, expenses also rose by 19% year-over-year to $4.7 billion, largely due to higher staff-related costs and infrastructure investments, according to Meta.
Meta CFO Susan Li described Reality Labs as a "strategic long-term priority," adding that the division will likely see "significant investment" as the company pursues its product roadmap.
<h1 class="wp-block-heading">Higher Losses Expected In 2024</h1>
Meta anticipates Reality Labs' operating losses to "increase meaningfully year-over-year" in 2024, attributing this to continued product development and scaling needs.
CEO Mark Zuckerberg noted the division's progress in integrating AI and wearables, pointing to the recent launch of the Ray-Ban Meta glasses as a milestone. 
There was little mention of Meta's latest Quest 3S mixed reality headset, though Zuckerberg emphasized its improved features over the Quest 3.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41643021/mark-zuckerberg-says-metas-open-source-gambit-is-paying-off-as-nvidia-and-amd-optimize-for-llama">Mark Zuckerberg Says Meta&#8217;s Open-Source Gambit Is Paying Off As Nvidia And AMD Optimize For Llama: &#8216;A Big Deal On Several Fronts&#8217;</a></li>
</ul>
Photo: Andrey Suslov via Shutterstock.

Tech

Meta's Reality Labs Faces $4.4 Billion Loss In AR/VR Sector

Goldman Sachs analyst Matthew Sykes maintains IQVIA Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) with a Buy and lowers the price target from $280 to $250.

Goldman Sachs Maintains Buy on IQVIA Hldgs, Lowers Price Target to $250

U.S. Baker Hughes Oil Rig Count -1 At 479; U.S. Baker Hughes Total Rig Count 585 (Unchanged)

Warning: TOVX is at high risk of performing badly

Theriva Biologics (TOVX) announced selection as one of five finalists for Merck KGaA's EMEA Advance Biotech Grant. Finalists for the grant will pre...

Theriva Biologics picked as finalist in competition for Merck KGaA's EMEA  grant

TOVX

Screenshot 2024-08-23 at 5.34.20 PM

Biotech

General

Theriva Biologics Receives Rare Pediatric Drug Designation From FDA For Treatment Of Retinoblastoma

Screenshot 2024-07-31 at 5.25.33 PM

Theriva Biologics Advances Its Product Pipeline To Improve Survival Rates For Many Difficult-To-Treat Cancers

Screenshot 2024-07-08 at 2.14.39 PM

Disproportionate Rise In Pancreatic Cancer Among Young Women Highlights High Unmet Need To Find Safe, Effective Treatments – Is Hope On The Horizon?

Screenshot 2024-06-06 at 5.27.01 PM

Theriva Biologics Receives Fast Track Designation From FDA For VCN-01 For Treating Metastatic Pancreatic Cancer

Screenshot 2024-04-16 at 5.31.31 PM

Theriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Difficult-To-Treat Cancers

Screenshot 2024-03-26 at 11.16.22 PM

Utilizing Common Viruses To Combat Dangerous Cancers – Hear From The Leaders Of This Biotech

Screenshot 2024-03-13 at 5.34.18 PM

How Theriva Biologics Is Using An Adenovirus To Develop A Novel Treatment For Pancreatic Cancer, As Well As Other Cancers With An Unmet Need

Screenshot 2024-03-05 at 6.31.45 PM

CADL

CGON

CLDI

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Screenshot 2024-02-28 at 6.54.06 PM

For The First Time The US Is Set To Hit 2 Million New Cancer Cases: Theriva Biologics Presents Novel Solutions To The Deadliest Cancers

Earnings

Press Releases

Theriva™ Biologics Reports Second Quarter 2024 Operational Highlights and Financial Results

Health Care

Theriva Biologics Announces Reverse Stock Split

Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program

Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Theriva Biologics Announces Pricing of $2.5 Million Public Offering

Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Bone Biologics

Bionomics Limited - American Depository Shares

Bionomics

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Molecular Templates

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Scorpius Holdings

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

TC BioPharm (Holdings) plc - American Depositary Shares

TC BioPharm (Holdings)

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

ZyVersa Therapeutics, Inc. - Common Stock

Comments

Theriva Biologics

Vendite allo scoperto

Theriva Biologics (AMEX:TOVX) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO